On December 10, 2020, Pfizer Inc. and BioNTech SE announced that the New England Journal of Medicine has published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. In the trial of 43,448 participants, who were 16 years and older, 21,720 of whom received BNT162b2 and 21,728 placebo, the two-dose regimen of 30 μg BNT162b2, which was given 21 days apart, was well-tolerated and demonstrated vaccine efficacy of 95% against COVID-19.
Support us by using this link when you shop on Amazon: https://www.amazon.com/Amazon-5-000-Coins/dp/B0096E8EC2?&_encoding=UTF8&tag=yunghealth-20&linkCode=ur2&linkId=839688fa30022bf270af7be621af9863&camp=1789&creative=9325
This video is based on original news release from Pfizer on December 10, 2020: https://bit.ly/3fT6jTa
Models featured in this video: https://bit.ly/2MptQjM
